Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 3, 2004, Pages 1385-1392

  Harro, Clayton D ^a   Judson, Franklyn N ^b   Gorse, Geoffrey J ^c   Mayer, Kenneth H ^d   Kostman, Jay R ^e   Brown, Stephen J ^f   Koblin, Beryl ^g   Marmor, Michael ^h   Bartholow, Bradford N ⁱ   Popovic, Vladimir ^j  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DENVER PUBLIC HEALTH   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d FENWAY INSTITUTE   (United States)

^e Philadelphia Field Initiating Group for HIV 1 Trials   (United States)

^f AIDS Research Alliance   (United States)

^g NEW YORK BLOOD CENTER   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j VaxGen Inc   (United States)

more..

Author keywords

AIDSVAX B B; Efficacy trial; HIV incidence; rgp120 HIV vaccine; Risk factors

Indexed keywords

AIDSVAX B B; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120;

ADULT; ADVERTIZING; ALTRUISM; ARTICLE; BISEXUALITY; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDUCATION; EPIDEMIOLOGICAL DATA; FEMALE; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; METHODOLOGY; MOTIVATION; MULTICENTER STUDY; NETHERLANDS; NUCLEIC ACID TEST; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; VACCINATION; VIREMIA; VIRUS DETECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ALTRUISM; BISEXUALITY; DOUBLE-BLIND METHOD; EDUCATIONAL STATUS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PATIENT SELECTION; PLACEBOS; REFERRAL AND CONSULTATION; RISK ASSESSMENT; VIREMIA;

EID: 7244229666     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000122983.87519.b5     Document Type: Article

References (32)

1. Esparza J. An HIV vaccine: how and when? Bull World Health Org. 2001;79:1133-1137.
2. MacQueen KM, Buchbinder SP, Douglas JM, et al. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials. AIDS Public Policy J. 1996;11:104-112.
3. Koblin BA, Taylor PE, Avrett S, et al. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS. 1996;10:1555-1561.
4. Buchbinder SP, Douglas JM Jr, McKirnan DJ, et al. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174:954-961.
5. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:266-271.
6. Bartholow BN, MacQueen KM, Douglas JM Jr, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.
7. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
8. Scheer S, Douglas JM Jr, Vittinghoff E, et al. Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:172-178.
9. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
10. Esparza J, Burke D. Epidemiological considerations in planning HIV preventive vaccine trials. AIDS. 2001;15(Suppl 5):S49-S57.
11. Heyward WL, MacQueen KM, Goldenthal KL. HIV vaccine development and evaluation: realistic expectations. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S205-S210.
12. Vermund SH. Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:628-631.
13. Dolin R. HIV vaccines for prevention of infection and disease in humans. Infect Dis Clin North Am. 2000;14:1001-1016.
14. Frey SE. HIV vaccines. Infect Dis Clin North Am. 1999;13:95-112.
15. Klein E, Ho RJ. Challenges in the development of an effective HIV vaccine: current approaches and future directions. Clin Ther. 2000;22:295-314.
16. Graham BS. Clinical trials of HIV vaccines. Annu Rev Med. 2002;53:207-221.
17. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S197-S203.
18. Boily MC, Masse BR, Desai K, et al. Some important issues in the planning of phase III HIV vaccine efficacy trials. Vaccine. 1999;17:989-1004.
19. Allen M, Israel H, Rybczyk K, et al. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses. 2001;17:667-674.
20. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S325-S331.
21. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S277-S289.
22. International Code of Harmonisation Good Clinical Practice Consolidated Guidelines. May 9, 1997. Available at: www.ich.org.
23. Procleix HIV-1/HCV assay package insert. IN0076-Clinical Trial Data.
24. Jackson JB, Smith K, Knott C, et al. Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol. 2002;40:2387-2391.
25. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol. 2002;40:2408-2419.
26. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
27. O'Connell JM, Hogg RS, Chan K, et al. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr. 2002;31:521-528.
28. Strathdee SA, Hogg RS, Martindale SC, et al. Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:61-66.
29. Strathdee SA, Hogg RS, Cornelisse P, et al. Factors associated with willingness to participate in HIV vaccine trials among HIV negative injection drug users and young gay and bisexual men. AIDS Behav. 2000;4:271-278.
30. Centers for Disease Control and Prevention. HIV incidence among young men who have sex with men-seven U.S. cities, 1994-2000. MMWR Morb Mortal Wkly Rep. 2001;50:440-444.
31. Valleroy LA, MacKellar DA, Karon JM, et al. HIV Prevalence and associated risks in young men who have sex with men. JAMA. 2000;284:198-204.
32. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2001. Atlanta: Centers for Disease Control and Prevention; September 2002. Available at: www.cdc.gov/std/stats.